COGT — Cogent Biosciences, Inc.

Is COGT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

Cogent Biosciences, Inc. (COGT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $36.85. The rating moved from Neutral to Oversold on August 11, 2026.

See all oversold Healthcare stocks →

AI analysis

Cogent Biosciences shows exposure to favorable structural themes in biologics, synthetic biology and CRO/CDMO demand driven by recent AI protein‑design activity. The company’s platform optionality and possible partnership or M&A interest provide upside catalysts, while a neutral market backdrop in the last trading window means moves will be driven largely by company updates and sector flows. Key near‑term constraints include execution risk, financing/dilution sensitivity, regulatory timelines, and competitive dynamics. Limited social and EDGAR signal flow increases information asymmetry and could elevate short‑term volatility. Under multiple scenarios, successful technical/partnership progress supports upside toward the provided targets, while setbacks or financing needs would increase downside pressure.

Key factors

  • Exposure to biologics/CRO/CDMO demand driven by AI-enabled protein design and synthetic‑biology workflows, which supports durable revenue opportunity for platform/service providers
  • Proprietary technology/platform that can enable differentiated therapeutic or service offerings (platform optionality increases long‑term upside)
  • Favorable M&A environment in biotech/pharma that can support acquisition interest or premium valuation multiples for differentiated assets
  • Balanced near‑term market context with steady order flow and selective growth interest, limiting immediate downside from market microstructure
  • Limited recent adverse macro or geopolitical drivers in the near window, allowing company‑specific fundamentals to dominate price action

Risks

  • Clinical or technical execution risk (trial failures, translational setbacks, or inability to scale platform are common in early/mid‑stage biotech)
  • Cash runway and dilution risk if additional financing is required to fund development; equity raises can pressure share price
  • Regulatory uncertainty and longer approval timelines which can delay commercialization and revenues
  • Competitive pressure from established CDMOs, large biologics players, and other synthetic‑biology vendors that could compress pricing or market share
  • Low social/research visibility and limited recent EDGAR disclosures reduce the information flow to investors, increasing volatility on news
  • Macro/sector rotation risk—if growth risk appetite wanes, smaller biotech names can see disproportionate multiple contraction

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for COGT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.